Selective tropism of the recombinant adeno-associated virus 9 serotype for rat cardiac tissue

Journal of Gene Medicine

Volumn 12, Issue 1, 2010, Pages 22-34

  Qi, Yanfei ^a   Liu, Xuan ^a   Li, Hongwei ^b   Shenoy, Vinayak ^a   Li, Qiuhong ^c   Hauswirth, William W ^c   Sumners, Colin ^b   Katovich, Michael J ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adeno associated virus; Cardiac selective; Rat

Indexed keywords

CAPSID PROTEIN; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 5; ADENO ASSOCIATED VIRUS 7; ADENO ASSOCIATED VIRUS 8; ADENO ASSOCIATED VIRUS 9; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FIBROBLAST; GENE TRANSFER; GENETIC TRANSDUCTION; HEART MUSCLE CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIVER; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SEROTYPE; VIROGENESIS; VIRUS GENOME; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; ANIMALS, NEWBORN; DEPENDOVIRUS; FIBROBLASTS; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; MYOCARDIUM; MYOCYTES, CARDIAC; ORGAN SPECIFICITY; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SEROTYPING; TISSUE DISTRIBUTION; TRANSDUCTION, GENETIC; TRANSGENES; VIRAL TROPISM;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS 9; RATTUS;

EID: 75449109180     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1404     Document Type: Article

References (36)

1. Yla-Herttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 2003; 9: 694-701.
2. Markkanen JE, Rissanen TT, Kivela A, Yla-Herttuala S. Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart - gene therapy. Cardiovasc Res 2005; 15(65): 656-664.
3. Bekeredjian R, Shohet RV. Cardiovascular gene therapy: angiogenesis and beyond. Am J Med Sci 2004; 327: 139-148.
4. Muller OJ, Katus HA, Bekeredjian R. Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc Res 2007; 73: 453-462.
5. Wright MJ, Wightman LM, Lilley C, et al. In vivo myocardial gene transfer: optimization, evaluation and direct comparison of gene transfer vectors. Basic Res Cardiol 2001; 96: 227-236.
6. Vandendriessche T, Thorrez L, Acosta-Sanchez A, et al. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost 2007; 5: 16-24.
7. Arruda VR, Stedman HH, Nichols TC, et al. Regional intravascular delivery of rAAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 2005; 105: 3458-3464.
8. Snyder RO,Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant rAAV vectors. Nat Genet 1997; 16: 270-276.
9. Woo YJ, Zhang JC, Taylor MD, Cohen JE, Hsu VM, Sweeney HL. One year transgene expression with adeno-associated virus cardiac gene transfer. Int J Cardiol 2005; 100: 421-426.
10. Chu D, Sullivan CC, Weitzman MD, et al. Direct comparison of efficiency and stability of gene transfer into the mammalian heart using adeno-associated virus versus adenovirus vectors. J Thorac Cardiovasc Surg 2003; 126: 671-679.
11. Vassalli G, Bueler H, Dudler J, von Segesser LK, Kappenberger L. Adeno-associated virus (rAAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors. Int J Cardiol 2003; 90: 229-238.
12. Romano G. Current development of adeno-associated viral vectors. Drug News Perspect 2005; 18: 311-316.
13. Du L, Kido M, Lee DV, et al. Differential myocardial gene delivery by recombinant serotype-specific adeno-associated viral vectors. Mol Ther 2004; 10: 604-608.
14. Muller OJ, Leuchs B, Pleger ST, et al. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 2006; 70: 70-78.
15. Duan D, Yan Z, Yue Y, Ding W, Engelhardt JF. Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation. J Virol 2001; 75: 7662-7671.
16. Palomeque J, Chemaly ER, Colosi P, et al. Efficiency of eight different rAAV serotypes in transducing rat myocardium in vivo. Gene Ther 2007; 14: 989-997.
17. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of rAAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008; 16: 1073-1080.
18. Bish LT, Morine K, Sleeper MM, et al. rAAV9 provides global cardiac gene transfer superior to rAAV1, rAAV6, rAAV7, and rAAV8 in the mouse and rat. Hum Gene Ther 2008; 19: 1358-1368.
19. Falcon BL, Stewart JM, Bourassa E, et al. Angiotensin II type 2 receptor gene transfer elicits cardioprotective effects in an angiotensin II infusion rat model of hypertension. Physiol Genomics 2004; 19: 255-261.
20. Zhang X, Azhar G, Nagano K, Wei JY. Differential vulnerability to oxidative stress in rat cardiac myocytes versus fibroblasts. J Am Coll Cardiol 2001; 38: 2055-2062.
21. Grobe JL, Der Sarkissian S, Stewart JM, Meszaros JG, Raizada MK, Katovich MJ. ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin Sci (Lond) 2007; 113: 357-364.
22. Zolotukhin S, Potter M, Zolotukhin I, et al. Production and purification of serotype 1, 2, and 5 recombinant adenoassociated viral vectors. Methods 2002; 28: 158-167.
23. QingK, MahC, HansenJ, ZhouS, DwarkiV, SrivastavaA. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999; 5: 71-77.
24. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445.
25. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999; 5: 78-82.
26. KaludovN, BrownKE, WaltersRW, ZabnerJ, ChioriniJA. Adeno-associated virus serotype 4 (rAAV4) and rAAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 2001; 75: 6884-6893.
27. Di Pasquale G, Davidson BL, Stein CS, et al. Identification of PDGFR as a receptor for rAAV-5 transduction. Nat Med 2003; 9: 1306-1312.
28. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. The 37/67-kilodalton laminin receptor is a receptor for adenoassociated virus serotypes 8, 2, 3, and 9. J Virol 2006; 80: 9831-9836.
29. Miyagi N, Rao VP, Ricci D, et al. Efficient and durable gene transfer to transplanted heart using adeno-associated virus 9 vector. J Heart Lung Transplant 2008; 27: 554-560.
30. Pacak CA, Mah CS, Thattaliyath BD, et al. Recombinant adenoassociated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006; 99: E3-E9.
31. Inagaki K, Fuess S, Storm TA, et al. Robust systemic transduction with rAAV9 vectors in mice: efficient global cardiac gene transfer superior to that of rAAV8. Mol Ther 2006; 14: 45-53.
32. Fechner H, Sipo I, Westermann D, et al. Cardiac-targeted RNA interference mediated by an rAAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. J MolMed 2008; 86: 987-997.
33. Yang L, Jiang J, Drouin LM, et al. A myocardium tropic adenoassociated virus (rAAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci USA 2009; 106: 3946-3951.
34. Suckau L, Fechner H, Chemaly E, et al. Long-term cardiactargeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 2009; 119: 1241-1252.
35. Sipo I, Fechner H, Pinkert S, et al. Differential internalization and nuclear uncoating of self-complementary adeno-associated virus pseudotype vectors as determinants of cardiac cell transduction. Gene Ther 2007; 14: 1319-1329.
36. Li W, Asokan A, Wu Z, et al. Engineering and selection of shuffled rAAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther 2008; 16: 1252-1260.